Herein, we examined the therapeutic potential of two selective enzyme inhibitors: AZD3241 (inhibiting MPO) and GSK484 (inhibiting PAD4) in ameliorating dextran sodium sulphate (DSS)-induced experimental colitis. This evidence concerns the gene PADI4 and colitis.